Ozmosi | Aceneuramic acid Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Aceneuramic acid

Alternative Names: aceneuramic acid
Clinical Status: Inactive
Latest Update: 2023-10-01
Latest Update Note: PubMed Publication

Product Description

Aceneuramic acid is an N-acetylneuraminic acid that is keto-neuraminic acid in which one of the hydrogens of the amino group is replaced by an acetyl group. It is a member of N-acetylneuraminic acids, a member of acetamides and a 2-oxo monocarboxylic acid. It derives from a keto-neuraminic acid. It is a conjugate acid of an aceneuramate.

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Saudi Arabia

Approved Indications: None

Known Adverse Events: None

Company: Ultragenyx
Company Location: Western America
Company Founding Year: 2010
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Distal Myopathies|GNE Myopathy

Phase 2: GNE Myopathy|Distal Myopathies|Thrombocytopenia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12618000188235p

SCI/D

N/A

Not yet recruiting

Unknown

2019-01-31

NCT02731690

UX001-CL203

P2

Terminated

Distal Myopathies|GNE Myopathy

2018-01-10

2019-03-20

Treatments

2015-004553-41

2015-004553-41

P2

Terminated

GNE Myopathy

2018-01-10

2022-03-13

Treatments

NCT02845609

SA-thrombo

P2

Completed

Thrombocytopenia

2017-09-01

2019-03-20

Treatments

NCT04671472

NPC-09-1

P3

Completed

GNE Myopathy|Distal Myopathies

2022-03-29

13%

2022-05-17

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT02736188

UX001-CL302

P3

Terminated

GNE Myopathy|Distal Myopathies

2018-01-10

2019-03-20

2016-000360-42

2016-000360-42

P3

Terminated

GNE Myopathy

2018-01-10

2025-07-09

Treatments

NCT02377921

GNEM

P3

Completed

GNE Myopathy|Distal Myopathies

2017-06-09

2019-03-20

Treatments

2014-005432-33

2014-005432-33

P3

Completed

GNE Myopathy

2017-06-09

2025-07-04

Treatments